Mirum puts Hepcludex in its sights with hep D readout
Mirum puts Hepcludex in its sights with hep D readout
Mirum Pharmaceuticals
Mirum Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing novel therapies for rare liver diseases, with marketed products LIVMARLI and CHOLBAM.
Company Info
Sector:Small Molecule Pharma
Headquarters:Foster City, California, USA
Founded:2018
Website:mirumpharma.com/
Upcoming Milestones & Key Dates
2026 H2
Clinical readout
Phase 2b/3 volixibat interim analysis in PBC
2027 H1
Clinical readout
Phase 3 BOLD study readout for brelovitug in chronic hepatitis D
Clinical Development Pipeline
LIVMARLI (maralixibat)
Target: IBAT (ileal bile acid transporter)CHOLBAM (cholic acid)
Target: Bile acid replacementVolixibat
Target: IBATRecent News
FDA nod for Mirum's Atebrioz makes 3 options for ultra-rare bone disease
FDA nod for Mirum's Atebrioz makes 3 options for ultra-rare bone disease
Mirum scores FDA approval for ultra-rare disorder
Rare disease pharma Mirum scored an approval for its ultra-rare bone lesion treatment it bought from Incyte.
Mirum, Incyte bolster case for approval in rare bone disease despite mid-stage miss
Mirum Pharmaceuticals and Incyte are pushing forward with regulatory submissions for their rare bone disease therapies despite mid-stage trial misses, citing subgroup and biomarker data to support approval.
Leadership Team
Chris Peetz
Co-Founder & CEO
Mike Grey
Executive Chairman
Ajay Narasimha
SVP Corporate Strategy & Business Development